176 related articles for article (PubMed ID: 30983508)
21. Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder.
Bishop JR; Najjar F; Rubin LH; Guter SJ; Owley T; Mosconi MW; Jacob S; Cook EH
Pharmacogenet Genomics; 2015 Nov; 25(11):548-54. PubMed ID: 26313485
[TBL] [Abstract][Full Text] [Related]
22. The Effects of Fluvoxamine on the Steady-State Plasma Concentrations of Escitalopram and Desmethylescitalopram in Depressed Japanese Patients.
Yasui-Furukori N; Tsuchimine S; Kubo K; Ishioka M; Nakamura K; Inoue Y
Ther Drug Monit; 2016 Aug; 38(4):483-6. PubMed ID: 27002781
[TBL] [Abstract][Full Text] [Related]
23. Genotyping of patients treated with selective serotonin reuptake inhibitors.
Solhaug V; Haslemo T; Kringen MK; Molden E; Dietrichs ES
Tidsskr Nor Laegeforen; 2022 Sep; 142(13):. PubMed ID: 36164782
[TBL] [Abstract][Full Text] [Related]
24. Age of onset for increased dose-adjusted serum concentrations of antidepressants and association with sex and genotype: An observational study of 34,777 individuals.
Tveit K; Hermann M; Nilsen RM; Wallerstedt SM; Rongve A; Molden E; Hole K
Eur J Clin Pharmacol; 2024 Mar; 80(3):435-444. PubMed ID: 38197945
[TBL] [Abstract][Full Text] [Related]
25. QT interval prolongation in users of selective serotonin reuptake inhibitors in an elderly surgical population: a cross-sectional study.
van Haelst IM; van Klei WA; Doodeman HJ; Warnier MJ; De Bruin ML; Kalkman CJ; Egberts TC
J Clin Psychiatry; 2014 Jan; 75(1):15-21. PubMed ID: 24345304
[TBL] [Abstract][Full Text] [Related]
26. Serotonergic Regulation and Cognition after Stroke: The Role of Antidepressant Treatment and Genetic Variation.
Damsbo AG; Kraglund KL; Buttenschøn HN; Johnsen SP; Andersen G; Mortensen JK
Cerebrovasc Dis; 2019; 47(1-2):72-79. PubMed ID: 30844812
[TBL] [Abstract][Full Text] [Related]
27. Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based Rotterdam Study.
Maljuric NM; Noordam R; Aarts N; Niemeijer MN; van den Berg ME; Hofman A; Kors JA; Stricker BH; Visser LE
Br J Clin Pharmacol; 2015 Oct; 80(4):698-705. PubMed ID: 25966843
[TBL] [Abstract][Full Text] [Related]
28. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation.
Beach SR; Kostis WJ; Celano CM; Januzzi JL; Ruskin JN; Noseworthy PA; Huffman JC
J Clin Psychiatry; 2014 May; 75(5):e441-9. PubMed ID: 24922496
[TBL] [Abstract][Full Text] [Related]
29. Effects of Cytochrome P450 (CYP) 2C19 Genotypes on Steady-State Plasma Concentrations of Escitalopram and its Desmethyl Metabolite in Japanese Patients With Depression.
Tsuchimine S; Ochi S; Tajiri M; Suzuki Y; Sugawara N; Inoue Y; Yasui-Furukori N
Ther Drug Monit; 2018 Jun; 40(3):356-361. PubMed ID: 29570504
[TBL] [Abstract][Full Text] [Related]
30.
Baumel WT; Poweleit EA; Neptune Z; Schroeder HK; Ramsey LB; Mills J; Strawn JR
J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):67-69. PubMed ID: 38377524
[No Abstract] [Full Text] [Related]
31. Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting.
Crépeau-Gendron G; Brown HK; Shorey C; Madan R; Szabuniewicz C; Koh S; Veinish S; Mah L
J Affect Disord; 2019 May; 250():341-345. PubMed ID: 30877856
[TBL] [Abstract][Full Text] [Related]
32. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH;
Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581
[TBL] [Abstract][Full Text] [Related]
33. Effects of Cytochrome P450 2C19 Genetic Polymorphisms on Responses to Escitalopram and Levels of Brain-Derived Neurotrophic Factor in Patients With Panic Disorder.
He Q; Mei Y; Liu Y; Yuan Z; Zhang J; Yan H; Shen L; Zhang Y
J Clin Psychopharmacol; 2019; 39(2):117-123. PubMed ID: 30742590
[TBL] [Abstract][Full Text] [Related]
34. Low-dose escitalopram for 2 days associated with corrected QT interval prolongation in a middle-aged woman: a case report and literature review.
Tseng PT; Lee Y; Lin YE; Lin PY
Gen Hosp Psychiatry; 2012; 34(2):210.e13-5. PubMed ID: 22133983
[TBL] [Abstract][Full Text] [Related]
35. Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients.
Jessel CD; Mostafa S; Potiriadis M; Everall IP; Gunn JM; Bousman CA
Pharmacogenet Genomics; 2020 Sep; 30(7):145-152. PubMed ID: 32433340
[TBL] [Abstract][Full Text] [Related]
36. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients.
Rudberg I; Mohebi B; Hermann M; Refsum H; Molden E
Clin Pharmacol Ther; 2008 Feb; 83(2):322-7. PubMed ID: 17625515
[TBL] [Abstract][Full Text] [Related]
37. Identification of a novel CYP2C19-mediated metabolic pathway of S-citalopram in vitro.
Rudberg I; Reubsaet JL; Hermann M; Refsum H; Molden E
Drug Metab Dispos; 2009 Dec; 37(12):2340-8. PubMed ID: 19773541
[TBL] [Abstract][Full Text] [Related]
38. Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder.
Shelton RC; Parikh SV; Law RA; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Macaluso M; Hain DT; Aguilar AL; Brown K; Lewis DJ; Jablonski MR; Greden JF
Psychiatry Res; 2020 Aug; 290():113017. PubMed ID: 32485484
[TBL] [Abstract][Full Text] [Related]
39. Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram).
Rudberg I; Hendset M; Uthus LH; Molden E; Refsum H
Ther Drug Monit; 2006 Feb; 28(1):102-5. PubMed ID: 16418702
[TBL] [Abstract][Full Text] [Related]
40. Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.
Ji Y; Schaid DJ; Desta Z; Kubo M; Batzler AJ; Snyder K; Mushiroda T; Kamatani N; Ogburn E; Hall-Flavin D; Flockhart D; Nakamura Y; Mrazek DA; Weinshilboum RM
Br J Clin Pharmacol; 2014 Aug; 78(2):373-83. PubMed ID: 24528284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
